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Abstract 
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. 
Most economies are struggling to deliver modern health care effectively. There is a need to support the transforma‑
tion of the health care system into integrated care with organizational health literacy.
Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the 
ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhi‑
nitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, 
are proposing real‑life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental 
exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self‑care 
through technology‑assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next‑
generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real‑world 
evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance 
in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good 
Practice in the field of digitally‑enabled, integrated, person‑centred care.
Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases 
to the digital transformation of health and care with a strong political involvement.
Keywords: Health care transformation, Care pathways, Rhinitis, ARIA, MASK, POLLAR
Background
In all societies, the burden and cost of non-communica-
ble diseases (NCDs) are increasing rapidly as advances in 
sanitation, public health measures and clinical care result 
in changes in demography [1]. Most, if not all, economies 
are struggling to deliver modern health care effectively 
[2]. Budgets will continue to be challenged with the move 
towards universal health coverage as demand increases 
and newer, more expensive technologies become avail-
able [3–5]. Traditional programmes, heavily reliant on 
specialist and supporting services, are becoming unaf-
fordable. Innovative solutions are required to alleviate 
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system wide pressures [6, 7]. There is a need to support 
authorities in the transformation of the health care sys-
tem into integrated care with organizational health lit-
eracy [8].
Integrated care pathways (ICPs) are structured multi-
disciplinary care plans detailing the key steps of patient 
care [9]. They promote the translation of guideline rec-
ommendations into local protocols and their application 
to clinical practice. They may be of particular interest in 
patients with multimorbidities since guidelines rarely 
consider them appropriately [10, 11]. An ICP forms all 
or part of the clinical record, documents the care given, 
and facilitates the evaluation of outcomes for continu-
ous quality improvement [12]. ICPs should be carried 
out by a multidisciplinary team including physicians, 
pharmacists [13, 14] and allied health care professionals 
[15]. ICPs should integrate recommendations from clini-
cal practice guidelines, but they usually (i) enhance rec-
ommendations by combining interventions, integrating 
quality assurance and (ii) describe co-ordination of care. 
Self-care and shared decision making are at the forefront 
of ICPs with the aim of empowering patients and their 
(professional and lay) care givers.
Rhinitis and asthma multimorbidity can be used as a 
model for chronic diseases since there is a broad agree-
ment on the ‘gold standard’ of care [16–18]. In allergic rhi-
nitis (AR) and asthma, adherence to treatment is a major 
unresolved problem [19, 20]. The vast majority of physi-
cians prescribe regular treatment but patients (and phy-
sicians when they are allergic [21]) do not adhere to the 
advice. Instead of they self-treat based on personal expe-
rience as suggested by real-world data [19, 22]. There is 
thus a major disconnect between physicians and patients, 
either because of the clinical approach utilised or due to 
a lack of patient health literacy, with insufficient shared 
decision making (SDM). On-demand (prn) approaches are 
now proposed in both diseases [23–25] and represent a 
major change from previous recommendations. This new 
approach should be integrated in ICPs, but it needs to be 
applied to self-management and based on solid evidence.
ICPs have been proposed with a focus on new tech-
nologies that, through personally-held data on tablet 
devices and recording of ‘symptom load’, should enhance 
self-management and adherence to guidelines and ICPs. 
The science of supporting self-care and ICPs through 
mobile devices (mHealth) is in its infancy, but prelimi-
nary results are encouraging [26–28]. In the context of 
asthma, a systematic review showed that mobile apps 
were generally as effective as traditional models of sup-
ported self-management, but that they may be preferred 
in some clinical and demographic contexts as being con-
venient as well as efficient for the patient and the profes-
sional [29]. Standardisation and the establishment of the 
Privacy Code of Conduct for mHealth apps [25] will be 
important in ensuring patients on the safeguard of their 
data and in helping them choose reliable technological 
tools, which will be essential for ICP implementation.
As an example for chronic disease care, a new develop-
ment of the ARIA initiative (ARIA phase 4) [30], along with 
POLLAR (Impact of Air POLLution on Asthma and Rhini-
tis), in collaboration with professional and patient organiza-
tions in the field of allergy and airway diseases, are proposing 
real-life ICPs centred around the patient with rhinitis, and 
using mHealth to monitor environmental exposure.
The current document was finalized and reviewed dur-
ing a meeting involving ARIA, POLLAR (Impact of Air 
POLLution on Asthma and Rhinitis (EIT Health)), the 
European Innovation Partnership on Active and Healthy 
Ageing and the Global Alliance against Chronic Respira-
tory Diseases (GARD, WHO Alliance). Major allergy 
societies and patient’s organizations participated in this 
meeting (Paris, December 3, 2018). The event was carried 
out with the support of many organizations (Fig. 1). 
The gaps in allergic rhinitis and asthma
AR is the most common chronic disease worldwide. 
Treatment guidelines have improved the knowledge on 
rhinitis and have had a significant impact on AR manage-
ment. However, many patients still fail to achieve suffi-
cient symptom control [31] and the costs for society are 
enormous, in particular due to a major impact on school 
and work productivity [32] and on allergic or non-allergic 
multimorbidities [33, 34]. Allergic Rhinitis and its Impact 
on Asthma (ARIA) has promoted the use of its recom-
mendations [16, 35, 36] to be integrated in ICPs using 
mobile technology in AR and asthma multimorbidity 
across the life cycle [37].
The clinical problem is that a large number of AR 
patients do not consult physicians because they think 
their symptoms are ‘normal’ and/or trivial, even though 
AR negatively impacts social life, school and work pro-
ductivity [36]. Many AR patients rely on over-the-coun-
ter (OTC) drugs and do not see the need to consult 
with physicians [38–41]. The vast majority of patients 
who visit general practitioners (GPs) or specialists have 
moderate-to-severe rhinitis [42–46]. ICPs should take 
this reality into account and consider a multi-disciplinary 
approach as proposed by AIRWAYS ICPs (Fig. 2).
Supported self‑management
People with AR and asthma are, by default, making day-
to-day decisions about the management of their condition 
(avoiding triggers, using various treatments and seeking 
professional advice). Reflecting this broad concept, self-
management is defined as “the tasks that individuals must 
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undertake to live well with one or more chronic condi-
tions. These tasks include having the confidence to deal 
with the medical management, role management and 
emotional management of their conditions” [47].
The term self-care includes generic “healthy lifestyle 
behaviours required for human development and func-
tioning” [48]. However, self-care and self-management 
overlap as, for example, smoking cessation is a generic 
Fig. 1 Organizations supporting the meeting
Fig. 2 ICPs for rhinitis and asthma multimorbidity (adapted from [102])
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self-care behaviour and a component of self-management 
for people with respiratory conditions.
Self-management support is the assistance that pro-
fessionals (pharmacy, primary care, specialist), patient’s 
organizations and other sources of information, as well 
as informal caregivers, give patients in order to make 
decisions about their condition and to manage disease 
and health-related tasks [49]. A taxonomy of 14 compo-
nents of self-management support [50] offers a pick-list 
of activities that may be considered when planning self-
management. These could be practical activities (e.g. 
teaching inhaler technique, discussing an action plan, 
helping to quit smoking) and imply SDM [50]. Mobile 
technology has the potential to contribute to many 
aspects of the supported self-management of chronic dis-
eases [51].
Supported self-management is a ‘key principle’ for ICPs 
in long-term conditions [52, 53]. This not only reflects 
the paradigm shift towards SDM, but also includes prag-
matic, economic imperatives, as healthcare systems 
respond to the increasing NCD burden. The economic 
impact of effective supported self-management goes 
beyond healthcare savings. For example, major economic 
return can be in the workplace where absenteeism and, 
more importantly, presenteeism are reduced [32] leading 
to an increased productivity.
Patient activation, defined as the “knowledge, skills and 
confidence a person has in managing his/her own health 
and health care” [54], is a goal of many ICP models. “Acti-
vation” encompasses the patients’ beliefs about their abil-
ity to self-manage (self-efficacy) and the likelihood that 
they will put these beliefs into action. Levels of activation 
range from the disengaged patients who let others man-
age their condition to the fully “activated” patients who 
embrace SDM and manage their health in partnership 
with their healthcare advisors, understanding the esca-
lation of treatment options and when to seek pharmacy 
or medical advice. Higher levels of activation have been 
associated with better process and health outcomes in 
adults [55] and there is some evidence that appropriately-
targeted self-management support may be more ben-
eficial to disadvantaged groups than to higher  literacy/
socioeconomic status patients.
Although ARIA appears to meet the patient’s needs, 
real-life data obtained using the Allergy Diary (MASK-
air®) app from around 10,000 people in 23 countries 
(Argentina, Austria, Australia, Belgium, Brazil, Can-
ada, Czech Republic, Denmark, Finland, France, Ger-
many, Greece, Italy, Lithuania, Mexico, Netherlands, 
Poland, Portugal, Spain, Sweden, Switzerland, UK. Bra-
zil is a developing country) have shown that very few 
patients are being treated according to guidelines and 
that they often self-medicate [19]. Self-medication is 
the treatment of common health problems with medi-
cines without medical supervision. It is important to 
ensure that well-written, short and accurate self-man-
agement information is available for people to pick 
up in pharmacies, or for download. In the case of AR, 
many patients have prescribed medications at home 
and, when symptoms occur, they use them. Self-care 
and SDM centred around the patient should be used 
more often [56]. ARIA has already followed a change 
management (CM) strategy embedding the AR-asthma 
multimorbidity in every day practice [30], but a new 
CM is now being considered to increase the benefits 
of self-care and SDM in ICPs using currently-available 
IT tools. In the case of AR and asthma multimorbid-
ity, aeroallergen exposure and pollution impact disease 
control and medications. However, there is currently no 
ICP in airway diseases that takes such environmental 
parameters into account [57]. These initiatives should 
prepare and support individuals, teams and organiza-
tions in making organizational change centred around 
the patient.
mHealth, such as apps running on consumer smart 
devices, is becoming increasingly popular and has the 
potential to profoundly affect health care and health out-
comes [58]. Several apps exist for AR and asthma [59–
63]. A review of the Apps in the field of allergic diseases 
has recently been completed (Matricardi et al. in prepa-
ration). One of the reviews—MASK (Mobile Airways 
Sentinel NetworK), the Phase 3 ARIA initiative [37, 64]—
is based on the freely-available MASK app (the Allergy 
Diary, Android and iOS platforms) for AR and asthma. 
Importantly, MASK is available in 17 languages and 
deployed in 23 countries [64]. Data from 26,000 users 
reporting over 200,000 days of treatment are available. It 
complies with the recent General Data Protection Regu-
lation (EU) 2016/679 (GDPR) enforced by the EU, May 
25, 2018 [65]. The GDPR aims primarily to give control 
to citizens and residents over their personal data and to 
simplify the regulatory environment by unifying the reg-
ulation within the EU [66, 67]. Importantly, MASK ena-
bles the assessment of treatment patterns in real life and 
provides detailed information on treatment, given that 
the Allergy Diary is able to distinguish between AR medi-
cations [19].
On‑line information
Most patients check on-line to help them decide what the 
problem is and how to address it. This is a crucial self-
management area of support and we need to think about 
how it can be optimized. Because of the multiplicity of 
sources and the lack of reliability control, it should be 
recognized that such a task would require an enormous 
effort. Consequently, it has been abandoned by many 
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other bodies/disease areas. One approach that may be of 
value in improving reliability would be to focus on sites 
that provide useful information and generate an accredi-
tation process with international standing.
Pharmacist care
Pharmacists are trusted health care professionals. Most 
patients with rhinitis are seen by pharmacists who are the 
initial point of contact of AR management in most coun-
tries. Depending on the country, few or most AR medica-
tions are available over-the-counter (OTC) [68–71] and 
are used by many patients. Therefore, as trusted health 
care professionals in the community, pharmacists are well 
placed to play a critical role identifying the symptoms of 
AR, recommending appropriate OTC treatment [38, 39, 
41] and integrating health care teams through ICPs [13, 
14]. The specific role of pharmacists in the management 
of AR within ICPs can been evidenced from several strat-
egies that have been initiated [72] or completed and from 
studies confirming the important impact of pharmacist 
interventions on AR outcomes [40, 70, 73–80].
ARIA in the pharmacy 2004 [38] is being revised in 
order to propose ICPs involving a multi-disciplinary 
approach. This paper has been built on the evidence and 
provides tools intended to help pharmacists give optimal 
advice/interventions/strategies to patients with rhinitis. 
The ARIA-pharmacy ICP includes a diagnostic question-
naire specifically focusing attention on key symptoms 
and markers of the disease, a systematic Diagnosis Guide 
(including a differential diagnosis) and a simple flow-
chart proposing treatment for rhinitis and asthma mul-
timorbidity. Key prompts for referral within the ICP are 
included. The use of technology is critical for enhancing 
the management of AR. The ARIA-pharmacy ICP should 
be adapted to local health care environments/situations 
as large regional or national differences in pharmacy-
based care exist.
Next‑generation guidelines
Practice guidelines contain evidence-based statements 
about treatment, tests, public health actions and policy 
decisions intended to assist recipients of care and their 
care providers in making informed decisions.
ARIA was one of the first chronic respiratory disease 
guidelines to adopt the GRADE (Grading of Recom-
mendation, Assessment, Development and Evaluation) 
approach, an advanced evidence evaluation and develop-
ment approach for guidelines [16, 81–83]. GRADE-based 
guidelines are available for AR from other organizations 
and their recommendations are similar [16–18]. How-
ever, a limitation of GRADE is that evidence often lacks 
applicability because the populations studied do not 
reflect most of the patients seen in primary care [84]. 
The GRADE recommendations are often based on RCT 
in which patients regularly use their treatment, whereas 
most AR or asthma patients are non-adherent. GRADE 
rarely includes recommendations based on implementa-
tion research.
The more recently completed work by the GRADE 
working group on its Evidence to Decision Frame-
works requires that guideline developers regularly 
address implementation and monitoring strategies 
[85–89]. Searching for and synthesizing evidence of 
effective implementation strategies enabled the BTS/
SIGN asthma guideline to make a recommendation on 
how supported self-management for asthma could be 
embedded into routine practice [90]. Strategies include 
proactively engaging and empowering patients, train-
ing and motivating professionals as well as providing an 
environment that promotes self-management and mon-
itors implementation [91]. In AR, cluster-randomized 
controlled trials have confirmed the overall value of 
guidelines [92, 93]. However, there has been only one 
direct testing of individual guideline recommendations 
in real–life studies in an effort to achieve optimization 
[94].
Next-generation ARIA-GRADE guidelines should con-
sider testing the recommendations based on the GRADE 
approach with real-world evidence (RWE) using data 
obtained by mHealth tools such as MASK in order to 
confirm the efficiency or to refine current GRADE-based 
recommendations. The first results of MASK confirm the 
feasibility of the project [19]. Adherence to treatment is 
very low as < 5% of users record symptoms and medi-
cations for a period of 2  weeks. This indicates that it is 
important to further test whether on-demand is equally 
or even more efficient than regular-continuous treatment 
and that guidelines should consider both regular and on-
demand treatment [19, 95].
Guideline recommendations often address isolated 
questions or focus on a single disease or problem. They 
should be considered in the context of the many deci-
sions that are made. ICPs try to address the multiple 
options and iterative changes in a patient’s status and 
problems. Guideline recommendations should support 
these iterative changes.
The key challenge for conventional treatment guide-
lines is that available evidence, both from randomized 
trials and non-randomized studies, does not usually 
address the complex pathways, but only affects isolated 
decision points within a pathway. For example, when an 
oral  H1-antihistamine is not achieving symptom control, 
we propose to replace it by an intra-nasal corticoster-
oid. However, this is often not the way that studies are 
designed and not how patients use these medications. 
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Assuming that properly developed pathways require 
evidence, our guidelines must start identifying the best 
available evidence to support decision points. When the 
evidence is indirect, which is frequently the case, con-
necting the relevant decision points and considering all 
of that evidence together results in low certainty on the 
overall structure and timing of an ICP.
The next-generation guidelines, if complemented by 
the intelligent use of tools such as MASK, which records 
patients’ symptoms and provides advice at given time 
points to follow ICPs, could exemplify unique new tools 
to both implement and evaluate recommendations in 
the context of pathways. Studies should be carried out in 
which patients are randomized to ICPs or to follow ARIA 
recommendations that are not presented as pathways. 
Such studies will provide both information on the use of 
the recommendations and on the usefulness of the path-
ways. Through implementation of recommendations, we 
will be able to increase our certainty in the evidence by 
evaluating the entire pathway and measuring outcomes 
in direct population-based studies that record what 
patients do as opposed to what clinicians prescribe (and 
patients do not do).
Study proposals of ARIA phase 4 and POLLAR
ARIA Phase 4 is the change management strategy for AR 
and asthma [96]. POLLAR is an EIT-Health (European 
Institute for Innovation and technology) project which 
aims to better understand, prevent and manage the 
impact of air pollution and allergen exposure on airway 
diseases [57]. POLLAR will use the MASK App, which 
is a Good Practice [64]. One of the POLLAR work-pack-
ages is the development of ICPs integrating aerobiology 
and air pollution. This will be developed using a step-
wise approach centred around the patient. The four-step 
project is a WHO Global Alliance against Chronic Res-
piratory Diseases (GARD) demonstration project.
Step 1: First meeting (December 3, 2018, Paris): 
Development of next‑generation ICPs with a focus 
on self‑management, pharmacy care and next‑generation 
guidelines
The Paris meeting addressed a number of areas as deline-
ated below (Fig. 3).
Step 2: 2019–2021: Further development 
and implementation of next‑generation ICPs
1. Develop a strategic and practical approach to 
improving patient autonomy and self-management 
programmes.
2. Deploy to other chronic respiratory diseases (asthma, 
COPD and rhinosinusitis [97]) and NCDs developing 
a multimorbidity App based on MASK expertise and 
experience.
3. Develop documents for specific age groups: pre-
school and school children, older adults.
4. Establish a best practice across several regions in 
the EU linking the study to policy makers aiming to 
improve air quality and outcomes in their population.
Step 3: Second meeting (December 2019): Embedding 
environmental data in next‑generation ICPs
Using the results obtained by POLLAR for air pollu-
tion, a second meeting will be held to integrate aerobi-
ology and air pollution data in mobile technology and to 
propose ICPs for the prevention of severe exacerbations 
and asthma during peaks of allergens and/or pollution. 
This meeting will also consider the deployment to other 
chronic diseases (Fig. 4) and the impact of biodiversity in 
chronic diseases [98].
Embedding next‑generation care pathways 
in the EU and global political agendas for allergic 
and chronic respiratory diseases
The Polish Presidency of the EU Council (2011) tar-
geted CRDs in children to promote their early recogni-
tion, prevention and management to ultimately impact 
active and healthy ageing (AHA) [99]. The develop-
mental determinants of CRDs in ageing were rein-
forced during the Cyprus Presidency of the EU Council 
“Healthy ageing across the lifecycle” (2012) [100] and 
an EU-NIH meeting held in Montpellier (2013) [101].
The objective of AIRWAYS-ICPs [102] was to launch 
a collaboration to develop multi-sectoral ICPs for CRDs 
in European countries and regions. AIRWAYS-ICPs was 
initiated in 2014 by the European Innovation Partnership 
on Active and Healthy Ageing (EIP on AHA, DG Santé 
and DG CONNECT) [103] as a GARD (Global Alliance 
against Chronic Respiratory Diseases) demonstration 
project [104]. In collaboration with GARD, the Directo-
rate General of Health of Portugal, the EIP on AHA and 
the Région Occitanie (France), a high-level meeting was 
organized July 1, 2015 with all major European scientific 
societies and patient’s organizations in Lisbon to review 
the implementation results of AIRWAYS ICPs [105].
Euforea (European Forum for Research and Education 
in Allergy and Airway Diseases) [56] proposed an annual 
stepwise strategy at the EU or ministerial levels. A Euro-
pean Symposium on Precision Medicine in Allergy and 
Airways Diseases was held at the EU Parliament October 
14, 2015 [106]. Another EU Parliament meeting was held 
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in Brussels March 29, 2017 on the Prevention and Self-
Management of CRDs using novel mobile health tools 
[37, 56, 97].
POLLAR (Impact of air POLLution on Asthma and 
Rhinitis, EIT Health) is focusing on the impact of 
allergens and air pollution on airway diseases and aims 
to propose novel ICPs integrating pollution, sleep and 
patients’ literacy and to assess the societal implications of 
the interaction [57].
Fig. 3 Next‑generation ICPs for rhinitis and asthma multi‑morbidity
Fig. 4 Embedding aerobiology and air pollution in ICPs
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Euforea organized an EU Summit in Vilnius, Lithu-
ania (March 2018) in collaboration with the Ministers of 
Health of Lithuania, Moldova, Georgia and Ukraine. The 
aim was to discuss and start the implementation of the 
POLLAR concepts, and to deploy it to EU neighboring 
countries. The Vilnius Declaration on Chronic Respira-
tory Diseases proposed multisectoral ICPs embedding 
guided self-management, mHealth and air pollution in 
CRDs [107].
The joint meeting discussed in this report (December 
3, 2018) proposed next-generation care pathways based 
on the Vilnius Declaration.
MASK has been selected by the  European Commis-
sion’s Directorate-General for Health and Food Safety 
(DG SANTE) and the newly-established Commission 
Expert Group “Steering Group on Health Promotion, 
Disease Prevention and Management of Non-Commu-
nicable Diseases” as a Good Practice (GP)  in the field 
of digitally-enabled, integrated, person-centred care.
On May 3, 2019, a Euforea-led meeting took place 
in the Parliament of Malta to review the results of the 
December 3 meeting and to propose practical strategies 
at the EU and global levels with GARD.
This new next-generation care pathway is completely 
aligned with the recommendations issued by the The-
matic Network SHAFE—Smart Healthy Age-Friendly 
Environments (approved by the European Commis-
sion—DG SANTE and DG CONNECT)—on its Joint 
Statement delivered 12th November 2018. The Statement 
underlined the need to patient empowerment and active 
involvement in its healthcare process and also urged the 
use of lifestyle medicine that provides effective impact on 
the patient’s wellbeing.
Conclusions
There is a need to support the digital transformation 
of health and care with integrated care. An innovative 
patient-centered approach is proposed by the ARIA 
expert group for rhinitis and asthma multimorbidity to 
be scaled up to chronic diseases.
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